Latasopt (Eye Drops)

Each ml contains latanoprost 0.05 mg.

- Increased IOP in patients with open-angle glaucoma and enhanced IOP;
- Tolerance to other drugs decreasing IOP and their low efficiency.

- Increased sensitivity to drug component.

Eye irritation (burning, itch, feeling of foreign substances after instillation), and also blackout, thickening and lengthening of eyelashes. Conjunctival hyperemia, transitory dotted epithelial erosions, blepharitis, increase of iris pigmentation.

Only for local use.
Drug is put in conjunctival sac of affected eye in dose 1 drop, 1 time a day in the evening. In case of missing dose the next administration is conducted in a usual regime (the dose is not doubled). The interval between instillations must be not less than 10 minutes at the co-administration of other topical ophthalmologic drugs.

Latasopt is not pharmaceutically incompatible thimerosal, as possible precipitation.
Drug can be also co-administered with medicines decreasing IOP (timolol, adrenoceptor agonist, acetasolamid, pilokarpin).

Before treatment the patients should be informed about the possibility of eye color changes. The treatment can be discontinued in case of intensive change of eye pigmentation. Using contact lens, they should be put down before dropping and again put on not early than in 15-20 minutes after drug instillation.

Latasopt may be used during pregnancy, when supposed usefulness for mother exceeds the potential risk for fetus. The drug should be carefully administered during lactation period as latanoprost and its metabolites can be excreted with human milk.

2.5 ml plastic vial with a dropper and screwing protective cap, equipped with protective ring.
1 vial in a carton box together with application instruction.


Dorzamed (Eye Drops)

Dorzasopt (Eye Drops)

Latamed (Eye Drops)

Latasopt (Eye Drops)

Normatin (Eye Drops)

 Events & Exhibitions


The most appropriate test to obtain for this patient is:

a. Blood pressure measurement
b. ANA
c. Chest X-ray
d. CD4 count

WOC 2014 in Tokyo, Japan
Online submission of abstracts will open on March 1, 2013. The deadline for abstract submission is July 26, 2013 at midnight in Tokyo. Submissions will be reviewed by the WOC 2014 Scientific Program Committee. Primary authors will be notified of acceptance by early October, 2013.

Researchers Develop Gene Therapy That Could Correct A Common Form Of Blindness
A new gene therapy method developed by University of Florida researchers has the potential to treat a common form of blindness that strikes both youngsters and adults.

Oxygen Therapy Helps Heal Chemical and Thermal Burns in the Eyes
Scientists at the Department of Ophthalmology, Ahvaz Jundishapur University of Medical Sciences, treated 24 eyes of 22 patients with acute chemical and thermal burns in their eyes.

Glaucoma Causes Higher Risk of Falls Among Older Adults
Glaucoma can affect a person's downward field of view, and this seems to be causing a higher risk of falls resulting in injury among older people with the eye disease.

Why Do Birds Fly into Power Lines? Is Poor Vision the Problem?
esearch suggests that collision with human structures is the largest unintended human cause of bird deaths

Diabetes and Hypertension Increase Glaucoma Risk
People with diabetes and/or hypertension are more likely to develop open-angle glaucoma (OAG) as well.

Be Careful Out There: Fireworks Caused 1,300 Eye Injuries in One Month in 2010
Sparklers caused about 200 U.S. eye injuries during a one-month period in 2010.

High Visual Perception Ability in Autistic People Explained
It has been noticed before that autistic people are highly able to process visual information, and this may be why.

Why Cold Temperatures Increase Eye Dryness
In fact, the meibum can solidify in cold temperatures and block the meibomian gland ducts

Home      |      Site Map      |      Terms of Use      |      Privacy Policy

2012 World Medicine Ophthalmics. All Rights Reserved.